NovaBridge Biosciences NBP
NASDAQ NBP
$1.81 +0.01 (+0.56%)
As of: Sep 4, 2026 · 2:57 PM EDT

NovaBridge Biosciences (NBP) Change in Cash (2019 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Change in Cash of -$17.4 million for Q4 2025, down 57.56% year-over-year from -$41.1 million in Q4 2024, and down 127.82% quarter-over-quarter from $62.7 million in Q3 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

NovaBridge Biosciences (NBP) Change in Cash (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Change in Cash for 4 consecutive years, with -$17.4 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Change in Cash fell 57.56% year-over-year to -$17.4 million; the TTM figure through Dec 2025 stood at -$38.5 million (down 109.86% YoY), while the FY2025 annual figure was $142.4 million, up 158.73% from the prior year.
  • Change in Cash fell to -$17.4 million in Q4 2025 per NBP's latest filing, from $62.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $62.7 million in Q3 2025 and bottomed at -$72.6 million in Q3 2024.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn 649.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -504.60 Mn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn -185.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - 374.50 Mn
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn 427.25 Mn
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn -2.94 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn - 225.59 Mn
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn -37.42 Mn
10 NovaBridge Biosciences 199.33 Mn 199.33 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -17.43 Mn
Sep 30, 2025 62.66 Mn
Dec 31, 2024 -11.06 Mn
Sep 30, 2024 -72.63 Mn
Dec 31, 2020 271.42 Mn
Sep 30, 2020 202.27 Mn
Dec 31, 2019 -12.45 Mn